Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 2, 2004, Pages 166-174

  Ishii, Ken J ^b   Gursel, Ihsan ^a   Gursel, Mayda ^a   Klinman, Dennis M ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

CpG DNA; Immunotherapy; Innate immunity; Suppressive ODNs; Toll like receptor 9

Indexed keywords

ALLERGEN; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ADJUVANT; OLIGONUCLEOTIDE;

ANIMAL; ARTICLE; CLASSIFICATION; CPG ISLAND; GENE THERAPY; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; METHODOLOGY; MOUSE; NEOPLASM; PHYSIOLOGY;

ADJUVANTS, IMMUNOLOGIC; ALLERGENS; ANIMALS; ANTINEOPLASTIC AGENTS; CPG ISLANDS; GENE THERAPY; HUMANS; IMMUNITY, NATURAL; IMMUNOTHERAPY; MICE; NEOPLASMS; OLIGONUCLEOTIDES;

EID: 7944219649     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Janeway CA Jr, Medzhitov R: Innate immune recognition. Annu Rev Immunol (2002) 20:197-216.
2. Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol (2001) 1(2):135-145.
3. Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu Rev Immunol (2003) 21:335-376.
4. Bird AP: Functions for DNA methylation in vertebrates. Cold Spring Harb Symp Quant Biol (1993) 58:281-285.
5. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S: A toll-like receptor recognizes bacterial DNA. Nature (2000) 408(6813):740-745.
6. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, Wagner H, Lipford GB: Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA (2001) 98(16):9237-9242.
7. Takeshita F, Leifer CA, Gursel I, Ishii KJ, Takeshita S, Gursel M, Klinman DM: Cutting edge: Role of toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol (2001) 167(7):3555-3558.
8. Bauer M, Redecke V, Ellwart JW, Scherer B, Kremer JP, Wagner H, Lipford GB: Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. J Immunol (2001) 166(8):5000-5007.
9. Kadowaki N, Antonenko S, Liu YJ: Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J Immunol (2001) 166(4):2291-2295.
10. Hemmi H, Kaisho T, Takeda K, Akira S: The roles of toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. J Immunol (2003) 170(6):3059-3064.
11. Tokunaga T, Yamamoto T, Yamamoto S: How BCG led to the discovery of immunostimulatory DNA. Jpn J Infect Dis (1999) 52(1):1-11.
12. Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol (2002) 20:709-760.
13. Wagner H: Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol (1999) 73:329-368.
14. Klinman DM, Verthelyi D, Takeshita F, Ishii KJ: Immune recognition of foreign DNA: A cure for bioterrorism? Immunity (1999) 11(2):123-129.
15. Ishii KJ, Takeshita F, Gursel I, Gursel M, Conover J, Nussenzweig A, Klinman DM: Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation. J Exp Med (2002) 196(2):269-274.
16. Hacker H, Vabulas RM, Takeuchi O, Hoshino K, Akira S, Wagner H: Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med (2000) 192(4):595-600.
17. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H: Bacterial CpG-DNA and lipopolysaccharides activate toll-like receptors at distinct cellular compartments. Eur J Immunol (2002) 32(7):1958-1968.
18. Klinman DM: Therapeutic applications of CpG-containing oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev (1998) 8(2):181-184.
19. Sethi S, Lipford G, Wagner H, Kretzschmar H: Postexposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet (2002) 360(9328):229-230.
20. Prinz M, Heikenwalder M, Schwarz P, Takeda K, Akira S, Aguzzi A: Prion pathogenesis in the absence of toll-like receptor signalling. EMBO Rep (2003) 4(2):195-199.
21. Klinman DM, Conover J, Coban C: Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect Immun (1999) 67(11):5658- 5663.
22. Gursel I, Gursel M, Ishii KJ, Klinman DM: Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol (2001) 167(6):3324-3328.
23. Zimmermann S, Egeter O, Hausmann S, Lipford GB, Rocken M, Wagner H, Heeg K: CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol (1998) 160(8):3627- 3630.
24. Juffermans NP, Leemans JC, Florquin S, Verbon A, Kolk AH, Speelman P, van Deventer SJ, van der Poll T: CpG oligodeoxynucleotides enhance host defense during murine tuberculosis. Infect Immun (2002) 70(1):147-152.
25. Pyles RB, Higgins D, Chalk C, Zalar A, Eiden J, Brown C, Van Nest G, Stanberry LR: Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J Virol (2002) 76(22):11387-11396.
26. Olbrich AR, Schimmer S, Heeg K, Schepers K, Schumacher TN, Dittmer U: Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs. J Virol (2002) 76(22):11397-11404.
27. Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM: Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol (1999) 162(4):2291-2298.
28. Gomis S, Babiuk L, Godson DL, Allan B, Thrush T, Townsend H, Willson P, Waters E, Hecker R, Potter A: Protection of chickens against Escherichia coli infections by DNA containing CpG motifs. Infect Immun (2003) 71(2):857-863.
29. Mutwiri G, Pontarollo R, Babiuk S, Griebel P, van Drunen Littel-van den Hurk S, Mena A, Tsang C, Alcon V, Nichani A, Ioannou X, Gomis S et al: Biological activity of immunostimulatory CpG DNA motifs in domestic animals. Vet Immunol Immunopathol (2003) 91(2):89-103.
30. Verthelyi D, Gursel M, Kenney RT, Lifson JD, Liu S, Mican J, Klinman DM: CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection. J Immunol (2003) 170(9):4717-4723.
31. Horner AA, Raz E: Immunostimulatory sequence oligodeoxynucleotide- based vaccination and immunomodulation: Two unique but complementary strategies for the treatment of allergic diseases. J Allergy Clin Immunol (2002) 110(5):706-712.
32. Kline JN, Kitagaki K, Businga TR, Jain VV: Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. Am J Physiol Lung Cell Mol Physiol (2002) 283(1):L170-L179.
33. Jain VV, Kitagaki K, Businga T, Hussain I, George C, O'Shaughnessy P, Kline JN: CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma. J Allergy Clin Immunol (2002) 110(6):867-872.
34. Tighe H, Takabayashi K, Schwartz D, Van Nest G, Tuck S, Eiden JJ, Kagey-Sobotka A, Creticos PS, Lichtenstein LM, Spiegelberg HL, Raz E: Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol (2000) 106(1 Pt 1):124-134.
35. Shirota H, Sano K, Kikuchi T, Tamura G, Shirato K: Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator. J Immunol (2000) 164(11):5575-5582.
36. Santeliz JV, Van Nest G, Traquina P, Larsen E, Wills-Karp M: Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol (2002) 109(3):455-462.
37. Creticos PS, Balcer SL, Schroeder JT, Hamilton RG, Chung B, Norman PS, Lichtenstein LM, Eiden JJ: Initial immunotherapy trial to explore the safety, tolerability and immunogenicity of subcutaneous injection of an Amb a 1 immunostimulatory oligonucleotide conjugate (AIC) in ragweed allergic adults. J Allergy Clin Immunol (2001) 107:S216.
38. Creticos PS, Eiden JJ, Broide D, Balcer-Whaley SL, Schroeder JT, Khattignavong A, Li H, Norman PS, Hamilton RG: Immunotherapy with immunostimulatory oligonucleotides linked to purified ragweed Amb a 1 allergen: Effects on antibody production, nasal allergen provocation, and ragweed seasonal rhinitis. J Allergy Clin Immunol (2002) 109(4):743 Abs 3.
39. Marshall JD, Abtahi S, Eiden JJ, Tuck S, Milley R, Haycock F, Reid MJ, Kagey-Sobotka A, Creticos PS, Lichtenstein LM, Van Nest G: Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes Th1 cytokine expression while downregulating Th2 cytokine expression in PBMCs from human patients with ragweed allergy. J Allergy Clin Immunol (2001) 108(2):191-197.
40. Choudhury BK, Wild JS, Alam R, Klinman DM, Boldogh I, Dharajiya N, Mileski WJ, Sur S: In vivo role of p38 mitogen-activated protein kinase in mediating the anti-inflammatory effects of CpG oligodeoxynucleotide in murine asthma. J Immunol (2002) 169(10):5955-5961.
41. Kline JN, Krieg AM, Waldschmidt TJ, Ballas ZK, Jain V, Businga TR: CpG oligodeoxynucleotides do not require Th1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. J Allergy Clin Immunol (1999) 104(6):1258-1264.
42. Chiaramonte MG, Hesse M, Cheever AW, Wynn TA: CpG oligonucleotides can prophylactically immunize against Th2-mediated schistosome egg-induced pathology by an IL-12-independent mechanism. J Immunol (2000) 164(2):973-985.
43. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM: Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. J Immunol (2001) 166(4):2372-2377.
44. Gursel M, Verthelyi D, Gursel I, Ishii KJ, Klinman DM: Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukocyte Biol (2002) 71(5):813-820.
45. Gursel M, Verthelyi D, Klinman DM: CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. Eur J Immunol (2002) 32(9):2617-2622.
46. Uhlmann E, Vollmer J: Recent advances in the development of immunostimulatory oligonucleotides. Curr Opin Drug Discov Devel (2003) 6(2):204-217.
47. Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M, Weiner GJ: Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol (2001) 167(9):4878-4886.
48. Blazar BR, Krieg AM, Taylor PA: Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. Blood (2001) 98(4):1217-1225.
49. Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, Jahrsdorfer B, Krug A, Rothenfusser S, Endres S, Hartmann G: Peritumoral CpG DNA elicits a coordinated response of CD8 T-cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol (2002) 169(7):3892-3899.
50. Cho HJ, Takabayashi K, Cheng PM, Nguyen MD, Corr M, Tuck S, Raz E: Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat Biotechnol (2000) 18(5):509-514.
51. Vicari AP, Chiodoni C, Vaure C, Ait-Yahia S, Dercamp C, Matsos F, Reynard O, Taverne C, Merle P, Colombo MP, O'Garra A et al: Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med (2002) 196(4):541-549.
52. Heckelsmiller K, Beck S, Rall K, Sipos B, Schlamp A, Tuma E, Rothenfusser S, Endres S, Hartmann G: Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol (2002) 32(11):3235-3245.
53. Jones TR, Obaldia N 3rd, Gramzinski RA, Charoenvit Y, Kolodny N, Kitov S, Davis HL, Krieg AM, Hoffman SL: Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine (1999) 17(23-24):3065-3071.
54. Davis HL, Suparto II, Weeratna RR, Jumintarto, Iskandriati DD, Chamzah SS, Ma'ruf AA, Nente CC, Pawitri DD, Krieg AM, Heriyanto et al: CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine (2000) 18(18):1920-1924.
55. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto l, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL et al: Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol (2000) 164(3):1617-1624.
56. Verthelyi D, Kenney RT, Seder RA, Gam AA, Friedag B, Klinman DM: CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol (2002) 168(4):1659-1663.
57. Takeshita S, Takeshita F, Haddad DE, Janabi N, Klinman DM: Activation of microglia and astrocytes by CpG oligodeoxynucleotides. Neuroreport (2001) 12(14):3029-3032.
58. Zheng M, Klinman DM, Gierynska M, Rouse BT: DNA containing CpG motifs induces angiogenesis. Proc Natl Acad Sci USA (2002) 99(13):8944-8949.
59. Zou W, Amcheslavsky A, Bar-Shavit Z: CpG oligodeoxynucleotides modulate the osteoclastogenic activity of osteoblasts via toll-like receptor 9. J Biol Chem (2003) 278(2):16732-16740.
60. Zou W, Schwartz H, Endres S, Hartmann G, Bar-Shavit Z: CpG oligonucleotides: Novel regulators of osteoclast differentiation. FASEB J (2002) 16(3):274-282.
61. Wagner H, Lipford GB, Hacker H: The role of immunostimulatory CpG-DNA in septic shock. Springer Semin Immunopathol (2000) 22(1-2):167-171.
62. Klinman DM, Kamstrup S, Verthelyi D, Gursel I, Ishii KJ, Takeshita F, Gursel M: Activation of the innate immune system by CpG oligodeoxynucleotides: Immunoprotective activity and safety. Springer Semin Immunopathol (2000) 22:173-183.
63. Krieg AM, Wu T, Weeratna R, Efler SM, Love-Homan L, Yang L, Yi AK, Short D, Davis HL: Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci USA (1998) 95(21):12631-12636.
64. Yamada H, Gursel I, Takeshita F, Conover J, Ishii KJ, Gursel M, Takeshita S, Klinman DM: Effect of suppressive DNA on CpG-induced immune activation. J Immunol (2002) 169(10):5590-5594.
65. Zhu FG, Reich CF, Pisetsky DS: Inhibition of murine dendritic cell activation by synthetic phosphorothioate oligodeoxynucleotides. J Leukocyte Biol (2002) 72(6):1154-1163.
66. Zhu FG, Reich CF, Pisetsky DS: Inhibition of murine macrophage nitric oxide production by synthetic oligonucleotides. J Leukocyte Biol (2002) 71(4):686-694.
67. Zeuner RA, Ishii KJ, Lizak MJ, Gursel I, Yamada H, Klinman DM, Verthelyi D: Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides. Arthritis Rheum (2002) 46(8):2219-2224.
68. Krieg AM, Love-Homan L, Yi AK, Harty JT: CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol (1998) 162(5):2428-2434.
69. Gramzinski RA, Doolan DL, Sedegah M, Davis HL, Krieg AM, Hoffman SL: Interleukin-12- and γ interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun (2001) 69(3):1643-1649.
70. Chiaramonte MG, Hesse M, Cheever AW, Wynn TA: CpG oligonucleotides can prophylactically immunize against Th2-mediated schistosome egg-induced pathology by an IL-12-independent mechanism. J Immunol (2000) 164(2):973-985.
71. Cho JY, Miller M, Baek KJ, Castaneda D, Nayar J, Roman M, Raz E, Broide DH: Immunostimulatory DNA sequences inhibit respiratory syncytial viral load, airway inflammation, and mucus secretion. J Allergy Clin Immunol (2001) 108(5):697-702.
72. Magone MT, Chan CC, Beck L, Whitcup SM, Raz E: Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. Eur J Immunol (2000) 30(7):1841- 1850.
73. Kohama Y, Akizuki O, Hagihara K, Yamada E, Yamamoto H: Immunostimulatory oligodeoxynucleotide induces Th1 immune response and inhibition of IgE antibody production to cedar pollen allergens in mice. J Allergy Clin Immunol (1999) 104(6):1231-1238.
74. Jahn-Schmid B, Wiedermann U, Bohle B, Repa A, Kraft D, Ebner C: Oligodeoxynucleotides containing CpG motifs modulate the allergic Th2 response of BALB/c mice to Bet v 1, the major birch pollen allergen. J Allergy Clin Immunol (1999) 104(5):1015-1023.
75. Dynavax Technologies Corp. Company Web Site (2004). http://www.dynavax.com/news.htm.